Autophagy is known to play a pivotal role in intracellular quality control through the degradation of damaged organelles and components. We previously reported that β-cell specific autophagy deficient mice (βAtg7KO), which lack Atg7 in β cells throughout their lives after birth, exhibited impaired glucose tolerance accompanied by decreased β-cell mass. Since the phenotypes in βAtg7KO mice result from life-long autophagic failure, it remains unclear as to when and how autophagy deficiency affects β-cell homeostasis. To address these questions, we have generated the inducible β-cell-specific Atg7-knockout mice (iβAtg7KO), by crossing mice carrying floxed Atg7 allele with MIP-Cre/ERT mice that induce Cre-mediated recombination in a tamoxifen-inducible manner under the control of mouse Ins1 promoter. When the autophagy deficiency was induced for 2 weeks (between 10 and 12 weeks of age), the iβAtg7KO2W mice exhibited normal glucose tolerance during IPGTT. On the other hand, the prolonged autophagy deficiency for 6 weeks (between 6 and 12 weeks of age) in iβAtg7KO6W mice caused glucose intolerance with significantly impaired insulin secretion. Thus, the short-term Atg7 deficiency in iβAtg7KO2W mice did not apparently deteriorate β-cell function, whereas the long-term Atg7 deficiency for 6 weeks in iβAtg7KO6W mice caused β-cell failure. In order to investigate the underlying molecular mechanisms by which the autophagy deficiency links to β-cell failure, RNA-sequencing was performed with the isolated islets from iβAtg7KO2w, iβAtg7KO6w mice and control littermates. Among more than 13,000 genes expressed in the islets, we identified a gene that was expressed >50-fold higher in iβAtg7KO2W and iβAtg7KO6w mice than in the control littermates, and that are highly expressed in diabetic db/db mice. Taken together, these findings suggest that the autophagy failure cumulatively leads to β-cell failure after a certain interval, accompanied by stepwise alteration of gene expression patterns.

Disclosure

L. Suzuki: None. T. Miyatsuka: None. M. Himuro: None. M. Miura: None. T. Katahira: None. K. Komiya: None. Y. Fujitani: Research Support; Self; Takeda Pharmaceutical Company Limited. Y. Nishida: None. H. Watada: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Kissei Pharmaceutical Co., Ltd., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Pfizer Inc., Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited. Speaker's Bureau; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk A/S, Ono Pharmaceutical Co., Ltd., Sanofi, Takeda Pharmaceutical Company Limited, Terumo Medical Corporation. Other Relationship; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Kowa Pharmaceutical Europe Co. Ltd., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Sanwa Chemical Industry Co. Ltd., Takeda Pharmaceutical Company Limited.

Funding

Japan Society for the Promotion of Science

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.